Trial Profile
Safety and Efficacy of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Coronary artery disease; Embolism and thrombosis; Peripheral arterial disorders; Stroke
- Focus Adverse reactions; Therapeutic Use
- 31 May 2018 New trial record
- 25 May 2018 Results published in the American Journal of Medicine